DOJ silent on appeal as UnitedHealth-Change deal close looms
A closed deal would be a major setback for the DOJ, which lost another merger case this year, antitrust legal experts told Healthcare Dive.
Centene’s string of settlements: $14M deal reached in Massachusetts
The most recent multimillion-dollar deal is the latest in a string of settlements Centene has reached over allegations it overcharged for prescription drugs and services.
With little data to go on, experts question how useful new Alzheimer’s drug will be
Positive results from a late-stage clinical trial of the drug, called lecanemab, were a surprising success for a field used to setbacks. But doctors and researchers point out that the reported benefit appears relatively modest.
Digital pathology picking up among US providers, vendors, report finds
Digital pathology technologies, already popular in Europe, are primed for growth in the U.S., according to a report from KLAS research.
Almost half of Americans have inadequate healthcare coverage, survey finds
Even as the uninsured rate has dipped to a record low, having coverage is not enough to protect consumers from the high-cost of care, Commonwealth Fund researchers found.
Positive Alzheimer’s trial results raise hopes for other experimental drugs
Expectations are now higher for amyloid-clearing drugs after lecanemab showed it can slow the disease’s progression in a large late-stage clinical trial.
Medicare Part B premium to drop for first time in a decade, Biden says
The reduction is tied to lower-than-expected spending for the controversial Alzheimer’s drug Aduhelm.
Mass General Brigham’s plan to slash millions in costs gets green light
The Massachusetts Health Policy Commission required the state’s largest health system to submit a cost-cutting plan, a first for the state board.
Stopgap Senate bill advances, but leaves COVID-19 funding behind
The bill cuts funding for COVID-19 and monkeypox aid but extends two rural hospital programs.
In surprise result, Alzheimer’s drug from Eisai, Biogen shows benefit in large trial
The companies said the drug, called lecanemab, met all of its goals in the Phase 3 study. The data are a significant finding and provide stronger support for a much-debated hypothesis for treating Alzheimer’s.